DekaBank Deutsche Girozentrale
TCRT icon

DekaBank Deutsche Girozentrale’s Alaunos Therapeutics TCRT Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-467
Closed -$133K – 1477
2021
Q3 		$133K Hold
467
– – ﹤0.01% 1266
2021
Q2 		$184K Hold
467
– – ﹤0.01% 1234
2021
Q1 		$232K Hold
467
– – ﹤0.01% 1160
2020
Q4 		$177K Buy
+467
New +$186K ﹤0.01% 1198

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DekaBank Deutsche Girozentrale's TCRT Position: Q4 2021 in Review

DekaBank Deutsche Girozentrale sold out of Alaunos Therapeutics (TCRT) in Q4 2021, closing a stake of 467 shares — an estimated $133K sold.

DekaBank Deutsche Girozentrale first reported a position in TCRT in Q4 2020 and held it in 4 quarters. The position peaked at $232K in Q1 2021. 165 funds tracked by Wall St. Rank hold TCRT as of Q4 2021.

  • DekaBank Deutsche Girozentrale reported no remaining Alaunos Therapeutics position as of Q4 2021 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 467 Alaunos Therapeutics shares in Q4 2021, an estimated $133K.
  • DekaBank Deutsche Girozentrale first reported a position in Alaunos Therapeutics in Q4 2020 and held it in 4 quarters.
  • DekaBank Deutsche Girozentrale's Alaunos Therapeutics position peaked at $232K in Q1 2021.
  • 165 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2021, filed 2 Feb 2022.